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Abstract
Background: Serum 25-hydroxyvitamin D3 (Vitamin D) insufficiency and single-nucleotide polymorphisms (SNPs)
on its receptor, Vitamin D receptor (VDR), have been reported to be involved in melanoma susceptibility in
populations mostly from northern countries.
Objective: To investigate 25-hydroxyvitamin D3 levels and VDR SNPs in melanoma patients from sunny area of
Barcelona, two studies were carried out. The first study evaluated the levels of Vitamin D at time of melanoma
diagnosis and the second one analyzed the association between VDR genetic variants and risk of having a high
nevus number, the strongest phenotypic risk factor for melanoma.
Methods: The levels of 25-hydroxyvitamin D3 in 81 melanoma patients at diagnosis were measured. In a second
group of melanoma patients, including 150 with low and 113 with high nevus number, 11 VDR SNPs were analyzed
for their association with nevus number.
Results: In the first study, 68% of patients had insufficient levels of 25-hydroxyvitamin D3 (<25 ng/ml). Autumn-
winter months and fair phototype were associated with 25-hydroxyvitamin D3 insufficiency; after multivariate
analysis, season of sampling remained the only independent predictor of 25-hydroxyvitamin D3 levels. In the
second study, VDR variant rs2189480 (P = 0.006) was associated with risk of high nevus number whereas rs2239179
(P = 0.044) and rs7975128 (P = 0.0005) were protective against high nevus number. After Bonferroni adjustment only
rs7975128 remained significant. In stratified analysis, SNP rs7975128 was found protective against multiple
melanomas (P = 0.021).
Conclusion: This study showed that even in Barcelona, a sunny Mediterranean area, 25-hydroxyvitamin D3 levels
were sub-optimal in the majority of melanoma patients at diagnosis. The involvement of VDR in nevi and, in turn,
in melanoma susceptibility has also been suggested. Larger studies are needed to confirm our findings.
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Background
Serum 25-hydroxyvitamin D3 (Vitamin D) is a hormone
classically known for its regulation of bone and calcium
metabolism. In recent years interest in 25-hydro-
xyvitamin D3 has grown as evidence has shown it to
play a role in cancer susceptibility and outcome,
postulated to be related to its anti-proliferative pro-apop-
totic and pro-differentiation properties [1,2]. Suboptimal
levels of 25-hydroxyvitamin D3 have been shown to be
associated with increased risk of several cancers including
melanoma [3,4]. Patients diagnosed with melanoma had
suboptimal levels of 25-hydroxyvitamin D3 in the North
of England within a few months of diagnosis, especially in
winter months [5] and a reduced level of 25-hydro-
xyvitamin D3 was associated with thicker melanomas,
poorer outcome [5] and aggressive melanoma [6]. There
are no reports of 25-hydroxyvitamin D3 levels in melan-
oma patients living in sunny Mediterranean countries and
we therefore herein report a small study in melanoma
patients from Barcelona.
Sunburn and intermittent sun exposure are the most
important environmental risk factors for melanoma [7]
but sun exposure is also the main source for 25-
hydroxyvitamin D3 photosynthesis. 25-hydroxyvitamin
D3 derives from cholesterol metabolites in skin after ex-
posure to ultraviolet B radiation (UVB) [8]. The skin
exposure to UVB induces the photolytic conversion of
7-dehydrocholesterol (7-DHC) to previtamin D and
from there to vitamin D3. The metabolic activation of
vitamin D3 requires two hydroxylation steps [9]. The
first hydroxylation occurs in the liver where vitamin D3
is converted in 25-hydroxyvitamin D3, the major circu-
lating metabolite of vitamin D3. The second hydroxyl-
ation transformed in the kidney the 25-hydroxyvitamin
D3 in 1,25-dihydroxyvitamin D3. While circulating 1,25-
dihydroxyvitamin D3 levels mainly reflect the synthesis
of 1,25-dihydroxyvitamin D3 in the kidney, 25-
hydroxyvitamin D3 serum levels are a good parameter of
whole body vitamin D status and for this reason is the
metabolite most measured for the classification of vita-
min D status [10]. In vitro, 25-hydroxyvitamin D3 has
been shown to inhibit the growth of normal melanocytes
and melanocytes derived from melanoma [11,12]. The
25-hydroxyvitamin D3 mediates its biological effects by
binding to its specific nuclear receptor, Vitamin D Re-
ceptor (VDR) [13].
The VDR gene, located on chromosome 12q13.11, has
more than 200 single-nucleotide polymorphisms (SNPs)
[14] but only a few SNPs, considered to be functional
[15], have been studied for their potential associations
with melanoma susceptibility [16-21]. Meta-analysis of
all reports published by 2009 supported the association
between VDR functional SNPs BsmI (rs1544410) and
FokI (rs2228570) and melanoma risk [22,23]. More
recently a large SNP study showed that common
inherited variants at VDR influence melanoma risk [24],
providing further evidence supporting a role for 25-
hydroxyvitamin D3 in melanoma susceptibility.
Common acquired nevi are melanocytes in proliferation
and high nevus number represents the strongest pheno-
typic risk factor for melanoma development [25,26].
Genome-wide association studies have identified common
susceptibility genes for melanoma and increased nevus
number [27,28].
If VDR SNPs are associated with melanoma risk there-
fore, elucidating the relationship between VDR variants
and nevi is an important step towards understanding the
involvement of VDR and, indirectly, of 25-hydroxy-
vitamin D3, in melanoma carcinogenesis.
The association between 25-hydroxyvitamin D3 levels
and/or inherited variation in VDR and melanoma risk
has been studied in few populations, mostly from north-
ern countries such as England, USA, Poland and
Germany [4,6,21-23]. Only two reports on VDR variants
have been published from southern European countries,
specifically Italy and Spain [18,29].
We presented the results of two studies performed in
Barcelona melanoma patients. The first study evaluated
the levels of 25-hydroxyvitamin D3 at time of melanoma
diagnosis and the second one analyzed the association
between VDR genetic variants and risk of having a high
nevus number.
Methods
Study design
Two cohort studies both including Caucasian melanoma
patients were carried out. The two studies were mutually
exclusive (each patient is present in only one study) and
included groups of patients belonging to two different
studies. In the first, a retrospective cohort study, 25-
hydroxyvitamin D3 levels were measured in serum
samples stored from melanoma patients at diagnosis for
the investigation of biomarkers. In the second, the associ-
ation between VDR variants and nevus number was
evaluated in a second cohort of melanoma patients
recruited to a genetic epidemiological study of nevi.
Patients were selected according to the total nevus num-
ber at the time of melanoma diagnosis and classified into
two groups: 150 cases with a low nevus number (<50 nevi)
and 113 cases with a high nevus number (>100 nevi). We
selected two groups of patients where there would be
no possible overlap between them, as <50 nevi were
closer to the normal nevus number in our population
[30] and >100 nevi being a well- documented risk factor
for melanoma [26].
Both cohort studies included melanoma patients from
the urban area of Barcelona recruited from the Melanoma
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Unit of Hospital Clinic of Barcelona. This is a referral
centre for Melanoma in the Catalonia region.
Both studies were approved by the Ethics Committee
of the Hospital Clinic of Barcelona and written informed
consent was obtained from all participants in the study.
The first set of melanoma patients (25-hydroxyvitamin D3
study)
The patients had all been diagnosed with melanoma be-
tween 2004–2008. Patients were those recruited to the
epidemiological study from which serum samples had
been cryopreserved in the Biobank of Hospital Clínic
and where the blood was collected within a maximum of
3 months after melanoma diagnosis. All patients had
localized tumors (stage I and stage II) except one (stage
IIIa) which had lymph node micrometastasis. Data on
gender, age at melanoma diagnosis, nevus number,
Fitzpatrick skin type, eye color, hair color, examined
actinic damage, number of melanoma, Breslow thick-
ness, reported solar exposure before 10 years of age,
between 10–18 and over 18 years were collected through
a questionnaire or extracted by medical records.
Participants were asked about weight, height and habits
of photoprotection via an interview.
The second set of melanoma patients (VDR
polymorphisms study)
A total of 263 melanoma patients were recruited be-
tween 2004–2007. The patients were selected according
to the total number of nevi at the time of melanoma
diagnosis and classified into two groups: 150 cases with
a low nevus number (cases with <50) and 113 cases with
a high nevus number (cases with >100). Total body
nevus number has been performed by dermatologists
and trained nurses. Data on gender, age at melanoma
diagnosis, nevus number, Fitzpatrick skin type, eye color,
hair color, examined actinic damage, number of melan-
oma, reported solar exposure as before 10 years of age,
between 10–18 and over 18 years were collected through
a questionnaire or extracted by medical records.
25-hydroxyvitamin D3 measurement
The levels of 25-hydroxyvitamin D3 (ng/ml) were
analyzed by a chemiluminescence immunoassay method
using the Liaison W kit (DiaSorin, Minnesota, USA) as
previously described [31]. This method has a detection
limit range from 4 ng/ml to 150 ng/ml. Insufficient level
of 25-hydroxyvitamin D3 was defined as less than 25 ng/ml
(60 nmol/L).
VDR polymorphisms genotyping
In total, 11 VDR SNPs rs7136534, rs11574027,
11168287, rs2238136, rs3782905, rs2189480, rs2239179,
rs11574077, rs11168267 and rs7975128 were analyzed.
All SNPs were selected as having minor allele frequencies
(MAF) ≥ 0.05 in HapMap (www.hapmap.org) European
individuals and at least one independent validation criter-
ion, as established in dbSNP (htpp://www.ncbi.nlm.nih.
gov/snp). The SNPs were selected using data from the
HapMap project and the Tagger tool [32] with linkage dis-
equilibrium r2 > 0.5.
Genomic DNA was isolated from peripheral blood
samples using the salting-out method. Genotyping was
performed with GenomeLab SNPstream genotyping
platform (Beckman & Coulter Inc. Fullerton, CA) and
its accompanying SNPstream software, according to the
manufacturer’s protocols. Primers were designed using
Autoprimer (http://www.autoprimer.com). The design of
the primers failed in the presence of adjacent SNPs or of
repeat sequence which can interfere with primers
annealing. If a selected SNP failed assay primer design, if
possible, an alternative tagging SNP in complete LD was
chosen. Two SNPs, FokI (rs2228570) and BsmI
(rs1544410), failed primer design. By HapMap, BsmI was
replaced with rs7975128 as in strong LD (r2 = 1) in the
Caucasian population while no other variants in LD
were found for FokI. Samples and SNPs with call rates
below 90% were excluded from the analysis. Failed
genotypes were not repeated. As quality controls, 10% of
samples were added as duplicates so that concordance
between genotype calls could be assessed. The genotyp-
ing assays were performed at the LIMM (Leeds) geno-
typing facilities.
Statistical method
Quantitative variables were described using median and
interquartile range (percentiles 25th and 75th). Inferential
analyses for these variables were performed by U
Mann–Whitney or Wilcoxon test for unpaired data.
Qualitative variables were tabulated by absolute frequen-
cies and percentages and evaluated using χ2 test or
Fisher’s exact test where appropriate.
25-hydroxyvitamin D3
The analysis was performed using SPSS v15.0 (SPSS Inc.,
Chicago IL). The level of statistical significance was set
at P < 0.05. Logistic regression was used to estimate
Odds Ratio (OR) and 95% Confidence Interval (CI)
for association between 25-hydroxyvitamin D3 levels
(<25 ng/ml) and gender, age diagnosis of melanoma
(<55/>55), BMI (normal weight/overweight/obese),
Fitzpatrick skin type (dark/fair), eye color (dark/light),
hair color (dark/light), actinic damage (no/yes); habits of
photoprotection (usually/never), solar exposure (none to
mild, that is under 50 hour per year (h/y) or moderate
to severe that is more than 50 (h/y)) before 10 years of
age, between 10–18 and over 18 years, number of mel-
anoma (single/multiple) and Breslow (<0.75 mm/0.75-
Ogbah et al. BMC Medical Genetics 2013, 14:26 Page 3 of 13
http://www.biomedcentral.com/1471-2350/14/26
1 mm/>1 mm). For the purpose of the analysis, Breslow
thickness was also analyzed as a continuous variable. The
lineal trend of association between 25-hydroxyvitamin D3
levels and Breslow thickness was evaluated by Spearman
correlation. In this cohort, cases with an intermediate
nevus number between 51 and 99 (51–99) were present;
nevus number variable included three groups (≤50 nevi),
(51–99) and (≥100 nevi).
To test the effect of the season on blood sampling as
an independent factor, a multivariate approach was
performed adjusting by phototype and gender.
VDR polymorphisms
Statistical analyses were performed using SNPassoc
package in R (version 2.10.1) [33]. Departure from
Hardy–Weinberg equilibrium (HWE) for each SNP was
assessed by χ2 test. Being a study including only cases,
SNPs found outside HWE were analyzed because HWE
could be informative for SNPs that confer risk rather
than genotyping error. To measure the association be-
tween VDR variant alleles and risk for increased number
of nevi, cases with less than 50 nevi were compared with
cases with more than 100 nevi, where cases <50 were
considered as the referent group.
The association between genotype and nevus number
was estimated using logistic regression and analyzed
under co-dominant, dominant, recessive and log-additive
models. Significance was defined as P < 0.05. The best in-
heritance model was selected using the Akaike criteria.
The reported ORs and 95% CI were adjusted for age and
gender. Significant associations between SNPs and nevus
number were also tested by the Bonferroni test. To con-
trol confounder variables, regression analysis was repeated
adjusting for whether there was a single or multiple
primaries. Logistic regression was also used to estimate
the association between polymorphisms and clinical
characteristics such as eye color (dark/light), hair color
(dark/light), Fitzpatrick skin phototype (dark/fair), actinic
damage (no/yes) and number of melanomas (single/mul-
tiple). Associations between VDR SNPs and solar expos-
ure (none-mild < 50 h/y/severe-moderate > 50 h/y) before
10, between 10–18 and over 18 years was evaluated by
interaction analysis.
Results
25-hydroxyvitamin D3
Medians levels of 25-hydroxyvitamin D3 and the clinical
characteristics of patients are shown in Table 1. A total
of 81 patients were analyzed, of whom 38 (47%) were fe-
male. For women, the median was 22.8 ng/ml and for
men, 19.59 ng/ml (P = 0.477). The median (25th - 75th
percentiles) age at melanoma diagnosis was 55 (36.7-
67.2). It was observed that younger patients (<55 years)
had slightly higher levels of 25-hydroxyvitamin D3
(median 22.5 ng/ml) than older patients (>55 years)
(median 19.7 ng/ml) (P = 0.441).
Serum 25-hydroxyvitamin D3 levels varied with the
season of venepuncture (Figure 1). The median level of
25-hydroxyvitamin D3 in April to September was 23.6 ng/
ml, exceeding the average of the 25-hydroxyvitamin D3
levels in October to March of 17.9 ng/ml (P = 0.017).
It is known that BMI influences 25-hydroxyvitamin D3
levels. The 25-hydroxyvitamin D3 levels were shown to be
lower (median 15.7 ng/ml) in obese patients with higher
BMI (BMI ≥ 30) than in overweight patients with BMI be-
tween 25–29.9 (median 19.6 ng/ml) and in normal weight
patients with BMI ≤ 24.9 (median 22.9 ng/ml) (P = 0.06).
Patients with phototype I/II had lower levels of 25-
hydroxyvitamin D3 (median 18 ng/ml) than patients
with phototype III/IV (median 22.9 ng/ml) (P = 0.005) in
univariate analysis. Those patients who reported
moderate/severe solar exposure before 10 years of age
(≥ 50 h/y) had higher levels of 25-hydroxyvitamin D3
(median 22.5 ng/ml) than those with none/mild solar ex-
posure (< 50 h/y) (median 16.8 ng/ml) (P = 0.019).
A higher percentage of patients with fair skin had
none/mild solar exposure (<50 h/y) than dark-skinned
patients in age groups <10 years (35% vs 12%; P = 0.06)
(unpublished observations). The use of sunscreen was
reported in 70% of patients. Skin type was also related
with sunscreen: 62% of patients with light skin
phototype usually used sunscreen compared with 29% in
patients with darker skin phototype (P = 0.023) (unpub-
lished observations).
As regards nevus number, patients with >100 showed
higher 25-hydroxyvitamin D3 levels (26.3 ng/ml) than
patients with 51–99 (20.2 ng/ml) or <50 nevi (21.2 ng/
ml) but no significant differences were found among the
three groups (P = 0.266).
Most of our patients (74%) had melanomas with
Breslow thickness ≤ 2 mm (range from 0.2 to 7.5 mm).
Breslow was analyzed both as continuous and categor-
ical variable. No statistically significant differences were
found between Breslow thickness and 25-hydroxyvitamin
D3 levels (r2 = 0.009, P = 0.42). The same result was
found when examining the association between Vitamin
D levels and Breslow as a categorical variable (P = 0.544).
No associations in levels of 25-hydroxyvitamin D3
were detected for actinic damage (P = 0.161), eye color
(P = 0.777), hair color (P = 0.912), photoprotection habits
before 10 (P = 0.569), between 10–18 (P = 0.672), over 18 -
years old (P = 0.824) and solar exposure between 10–18
(P = 0.08), over 18 years old (P = 0.267) and number of
melanomas (P = 0.992) (Table 1).
25-hydroxyvitamin D3 level was also evaluated as a di-
chotomous variable. Two categories were defined: appro-
priate levels >25 ng/ml and insufficient levels ≤25 ng/ml.
The cut off at 25 ng/ml was chosen as it is the range
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where the parathyroid hormone has its maximum inhib-
ition [34]. Using this definition, 32% of patients had ad-
equate levels (>25 ng/ml) and 68% had insufficient levels
(≤25 ng/ml) of 25-hydroxyvitamin D3 (Table 2).
The relationship between 25-hydroxyvitamin D3 levels,
as a dichotomous variable, and clinical characteristics was
showed in Table 2. The group with insufficient 25-
hydroxyvitamin D3 level (≤25 ng/ml) differed from
those with appropriate 25-hydroxyvitamin D3 (>25 ng/ml)
in season of blood sampling (P = 0.012), solar exposure
between 10–18 years (P = 0.049) and skin type (P = 0.05)
(Table 2). Since patient recollection of solar exposure
Table 1 Descriptive analysis of characteristics and medians of 25-hydroxyvitamin D3 levels at time of diagnosis in
melanoma patients
Variables Nº patients* Vitamin D levels
ng/ml
P
Clinical characteristic* Age at diagnosis of melanoma (years) <55 40 22.5(16.8- 33.4) 0.441
≥55 41 19.7(16.4- 24)
Gender Male 43 19.5(13.8- 26) 0.477
Female 38 22.8(17.8- 32.6)
BMI (kg/m2) Normal weight 24 22.9(19.2- 31.6) 0.063
Overweight 24 19.6(15.3- 26.3)
Obese 15 15.7(11.4- 25.4)
Fitzpatrick skin type Dark 37 22.9(19.4- 32.6) 0.005
Fair 44 18(15.5- 24.4)
Hair color Dark 53 21.6(16.8- 26.6) 0.912
Light 23 22.4(16.4- 30.6)
Eye color Dark 38 20.5(13.2- 26.2) 0.777
Light 37 22.2(17.3- 32.5)
Actinic damage No 62 22(16.6- 29.3) 0.161
Yes 16 18.5(16.3- 32.6)
Nevus Number <50 34 21.2(13.7- 29.9) 0.266
51-99 17 20.2 (17.8- 24.3)
>100 12 26.05 (19–36.6)
Habits of solar exposure
and photoprotection
Solar exposure before 10 years old None/Mild 19 16.8(12–27.4) 0.019
Severe/Moderate 59 22.5(17.3- 30.6)
Solar exposure 10–18 years old None/Mild 20 17.8(14.5- 22.5) 0.08
Severe/Moderate 57 22.9(17.3- 32.6)
Solar exposure over 18 years old None/Mild 11 17.7(16.4- 23.9) 0.267
Severe/Moderate 29 22.6(16.8- 30.2)
Photoprotection before 10 years old Usually 25 22.6(17.3- 27.4) 0.569
Never 47 20.8(15.7- 31.1)
Photoprotection 10–18 years old Usually 16 22.6(17.4- 27) 0.672
Never 33 21.8(16.6- 32.5)
Photoprotection over 18 years old Usually 35 19.7(16.8- 27.4) 0.824
Never 36 21.7(16–31.8)
Melanoma characteristic* Number of Melanoma SPM 62 20.5(16.4- 27.4) 0.992
MPM 19 21.6(16.8- 31.1)
Breslow thickness <= 0.75 31 19(13.8- 29.3) 0.544
0.75-1 15 22.2(17.8- 26)
> = 1 22 23.1(16.6- 31.1)
The medians (25th - 75th percentiles) of 25-hydroxyvitamin D3 levels were reported. P-values were calculated by U Mann Whitney or Wilcoxon test.
*Not all the patients have complete data.
Ogbah et al. BMC Medical Genetics 2013, 14:26 Page 5 of 13
http://www.biomedcentral.com/1471-2350/14/26
may be subject to response and recall bias, solar ex-
posure variable was not included in multivariate
analysis.
After multivariate logistic regression analysis, season
of sampling remained the only predictors of 25-
hydroxyvitamin D3 levels, independent of gender or skin
type (Table 3).
VDR polymorphisms
Clinical characteristics, habits of solar exposure and mel-
anoma data of patients are resumed in Table 4. The me-
dian age at melanoma diagnosis was 45 years (33–59.8),
considering all patients. Significant differences between
cases with <50 nevi and cases with >100 nevi were found
such as age at melanoma diagnosis (P < 0.001) and num-
ber of melanomas (P < 0.001) (Table 4). Patients with
multiple nevi were younger (median 39 years) and have
more multiple melanomas (55%) than patients with few
nevi (median 49 years; 20% with melanoma multiple).
A total of 10 out of 11 SNPs were successfully
genotyped in 263 melanoma patients. SNP rs739837
(BglI) failed genotype analysis. All the 10 SNPs followed
HWE in the reference group (cases with <50) (Table 4).
Genotyping quality was confirmed with 100% concord-
ance between duplicates.
Differences in genotype distributions between cases
with <50 nevi and cases with >100 nevi were significant
for 3 VDR SNPs: rs2189480 (OR = 1.80, 95%IC (1.17-
2.76); Padditive = 0.006), rs2239179 (OR = 0.67, 95%IC
(0.46-0.99); Padditive = 0.044) and rs7975128 (OR = 0.51,
95%IC (0.35-0.76); Padditive = 0.0005), adjusted for age
and gender. An additional SNP rs3782905, significant
under recessive model (OR =0.21, 95%IC (0.07-0.66);
Precessive = 0.0025), was not further considered as this
effect is likely due to small number of individuals homo-
zygous for this rare allele with high nevus number. Use
of the Bonferroni test supported a significant association
with nevus number only for rs7975128. Although SNP
rs2239179 was no longer significant (Padditive = 0.06),
adjustment for number of melanomas, as confounding
variable, did not result in substantial OR variation for all
three SNPs (Table 5).
Sub-group analysis revealed that rs7975128 was
associated with decreased risk of multiple primary mel-
anoma (OR = 0.64 95%CI (0.43-0.94); Padditive = 0.021)
and with light eye color (OR = 1.48 95%CI (1.00-2.19);
Padditive = 0.049).
Discussion
Our work is the first study to describe 25-hydroxyvitamin
D3 insufficiency in melanoma patients from Spain. Fur-
thermore, the association between VDR SNPs and nevus
number, an established risk factor for melanoma, was also
evaluated.
The optimal level of 25-hydroxyvitamin D3 remains
contentious4. Several meta-analyses support the evidence
that low 25-hydroxyvitamin D3 serum level, which is
highly prevalent worldwide, is a risk factor for many
chronic diseases including cancer [35]. The minimum
desirable serum level of 25-hydroxyvitamin D3 has been
suggested to be between 20 ng/ml and 30 ng/ml [36]. In
Figure 1 Variation in serum 25-hydroxyvitamin D3 levels by season of blood sampling. The circles represent high 25-hydroxyvitamin D3
values (38.2 ng/ml and 41 ng/ml) and the asterisk the highest 25-hydroxyvitamin D3 value 61.7 ng/ml.
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Table 2 Association between clinical characteristics and suboptimal 25-hydroxyvitamin D3 levels at time of diagnosis
in melanoma patients
Variables* VitD level
sufficient
>25 ng/mL
VitD level
insufficient
≤25 ng/mL
OR (95%IC) P
n = 26(32%) n = 55(68%)
Clinical characteristic Age at diagnosis of melanoma** 54 (36–65) 55 (37–68) 0.99 (0.96- 1.01) 0.553
Gender Female 15 (57.7%) 23 (41.8%) 1
Male 11 (42.3%) 32 (58.2%) 1.9 (0.74- 4.88) 0.184
BMI basal (kg/m2) Normal weight 9 (47.4%) 15 (34.1%) 1
Overweight 6 (31.6%) 18 (40.9%) 0.56 (0.16- 1.92) 0.353
Obese 4 (21.1%) 11 (25%) 0.61 (0.16- 2.49) 0.487
Season blood sampling Spring- Summer 18 (69.2%) 20 (38.5%) 1
Autumn- Winter 8 (30.8%) 32 (61.5%) 3.6 (1.32- 9.81) 0.012
Fitzpatrick skin type Dark 16 (61.5%) 21 (38.2%) 1
Fair 10 (38.5%) 34 (61.8%) 2.59 (0.99- 6.76) 0.052
Hair color Dark 8 (30.8%) 32 (61.5%) 1
Light 8 (32%) 15 (29.4%) 0.89 (0.32- 2.49) 0.818
Eye color Dark 11 (44%) 27 (54%) 1
Light 14 (56%) 23 (46%) 0.67 (0.26- 1.76) 0.415
Actinic damage No 21 (80.8%) 41 (78.8%) 1
Yes 5 (19.2%) 11 (21.2%) 0.89 (0.27- 2.89) 0.843
Nevus Number <50 12 (54.5%) 22 (53.7%) 1
≥50 10 (45.5%) 19 (46.3%) 0.97 (0.34- 2.73) 0.946
Habits of solar exposure
and photoprotection
Solar exposure before 10 years old Severe/Moderate 21 (80.8%) 38 (73.1%) 1
None/Mild 5 (19.2%) 14 (26.9%) 1.55 (0.49- 4.9) 0.458
Solar exposure 10–18 years old Severe/Moderate 23 (88.5%) 34 (66.7%) 1
None/Mild 3 (11.5%) 17(33.3%) 3.83 (1.01- 14.5) 0.049
Solar exposure > 18 years old Severe/Moderate 11 (91.7%) 18 (64.3%) 1
None/Mild 1 (8.3%) 10 (35.7%) 6.11 (0.68- 54.5) 0.105
Photoprotection before 10 years old Never 17 (68%) 30 (63.8%) 1
Usually 8 (32%) 17 (36.2%) 1.20 (0.43- 3.37).33) 0.724
Photoprotection 10–18 years old Never 14 (73.3%) 19 (63.3%) 1
Usually 5 (26,3%) 11 (36.7%) 1.62 (0.46- 5.73) 0.453
Photoprotection over 18 years old Never 15 (60%) 21 (45.7%) 1
Usually 10 (40%) 25 (54.3%) 1.79 (0.66- 4.80) 0.250
Melanoma characteristic Number of Melanoma SPM 24 (92.3%) 49 (89.1%) 1
MPM 2 (7.7%) 6 (10.9%) 0.68 (0.13- 3.63) 0.652
Breslow thickness+ <= 0.75 22 (46.8%) 9 (42.9%) 1
0.75-1 11 (23.4%) 4 (19.0%) 0.89 (0.22- 3.54) 0.867
> = 1 14 (29.8%) 8 (38.1) 1.4 (0.43- 4.48) 0.574
Breslow thickness+** 0.8 (0.52- 1.3) 0.8 (0.52- 1.2) 1.1 (0.78- 1.54) 0.583
VitD = 25-hydroxyvitamin D3 *Not all the patients have complete data +Breslow thickness was analized as categorical and continuos variable **The medians
(25th - 75th percentiles) of 25-hydroxyvitamin D3 levels were reported for age at diagnosis of melanoma and breslow thickness.
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2011 The IOM committee reported guidelines stating
that a level of 25-hydroxyvitamin D3 >20 ng/ml is
needed for good bone and general health for practically
all individuals [37]. However, the IOM report did not
consider clinical and demographic variables (ie: race/eth-
nicity, adiposity, body composition, sun exposure, etc.)
by which 25-hydroxyvitamin D3 levels are notoriously
affected. Recently, a meta-analysis involving 59 231
healthy subjects from eleven prospective cohort studies
suggested that the optimal 25-hydroxyvitamin D3
concentrations of between 30 ng/ml and 40 ng/ml (75 -
nmol/L and 100 nmol/L) are needed to reduce mortality
[38]. The majority of authors site the cut off as <30 ng/ml
as this level is reported to correlate with leveling off of the
parathyroid hormone (PTH) level. The level chosen as cut
off varied in studies in European populations [39]. In our
study a conservative level of ≤25 ng/ml as 25-hydro-
xyvitamin D3 insufficiency was chosen as reported in a
previous study in melanoma patients [5]. Using this defin-
ition, most of our patients (68%) at the time of melanoma
diagnosis had suboptimal levels of 25-hydroxyvitamin D3.
Newton-Bishop et al. [5] determined the levels of 25-
hydroxyvitamin D3 in 1132 patients with melanoma from
the North of England (Leeds), where insufficient levels of
25-hydroxyvitamin D3 was found in 64% of patients, a
proportion comparable to our study. In the same study,
25-hydroxyvitamin D3 levels were associated with Breslow
thickness. In contrast to the UK study, we did not found
any association between 25-hydroxyvitamin D3 and
Breslow thickness as the majority of our melanoma
patients has Breslow thickness <2 mm.
The prevalence of insufficiency in Spain, a Mediterra-
nean country with many hours of sunshine and where
tanning is considered indicative of a healthy and attract-
ive status, was therefore unexpected. 25-hydroxyvitamin
D3 levels in general Spanish population have been
reported to be insufficiency by studies tended to be small
Table 3 Multivariate models for prediction of presence of
low levels of 25-Hydroxyvitamin D3
N Model Variables OR (95%CI) P
1 Season blood sampling
(October- March)
3.25 (1.17-9.03) 0.024
Skin phototype (Fair) 2.21 (0.81- 6.04) 0.123
2 Season blood sampling
(October- March)
3.3 (1.17- 9.27) 0.024
Skin phototype (Fair) 2.33 (0.84- 6.46) 0.105
Gender (Male) 1.88 (0.68- 5.21) 0.227
Model 1. Estimation of presence of low levels of 25-Hydroxyvitamin D3 by
season blood sampling adjusted by skin phototype.
Model 2. Estimation of presence of low levels of 25-Hydroxyvitamin D3 by
season blood sampling adjusted by skin phototype and gender.
Multivariate logistic regression models for estimation of presence of low levels
of 25-Hydroxyvitamin D3 suggest that season blood sampling in autumn-
winter (October-March) months is the only predictor of low 25-Hydroxyvitamin
D3, independently from skin phototype and gender.
Table 4 Clinical characteristics of patients with low (<50) and high (>100) nevus number
Variables* Cases <50(%)
n = 150
Cases >100(%)
n = 113
P
Clinical characteristic Age at melanoma diagnosis* 49(34–64) 39(32–50) <0.001
Gender Male 68(45.3) 51(45.1) 1.000
Female 82(54.7) 62(54.9)
Fitzpatrick skin type Dark 80(58.4) 43(45.7) 0.061
Fair 57(41.6) 51(54.3)
Hair colour Dark 107(77.5) 71(75.5) 0.723
Light 31(22.5) 23(24.5)
Eye colour Dark 90(66.2) 60(64.5) 0.795
Light 46(33.8) 33(35.5)
Actinic Damage No 99(85.3) 64(85.3) 0.988
Yes 17(14.7) 11(14.7)
Habits of solar exposure Solar exposure before 10 years old None/Mild 53(41.4) 28(29.5) 0.067
Severe/Moderate 75(58.6) 67(70.5)
Solar exposure 10–18 years old None/Mild 30(23.8) 26(27.7) 0.517
Severe/Moderate 96(76.2) 68(72.3)
Solar exposure over 18 years old None/Mild 26(20.6) 24(25.8) 0.367
Severe/Moderate 100(79.4) 69(74.2)
Melanoma characteristic Number of melanoma SPM 120(80) 50(44.2) <0.001
MPM 30 (20) 63(55.8)
*Not all the patients have complete phenotype data.**The median (25th - 75th percentile) of age at diagnosis of melanoma was reported.
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Table 5 Association between VDR polymorphisms and nevus number
SNP Position* Change MAF% HWE P^ Genotype Cases <50(%) Cases >100(%) OR (95%CI)a Padditive
a OR (95%CI)b Padditive
b
1 rs7136534 48294626 C/T 0.18 0.400 C/C 101 (68.7) 70 (65.4) 1.00
T/C 40 (27.2) 33 (30.8) 1.15 (0.65- 2.02)
T/T 6 (4.1) 4 (3.7) 0.78 (0.21- 2.94)
additive 1.03 (0.65- 1.62) 0.903 1.18 (0.73- 1.92) 0.504
2 rs11574027 48287373 G/T 0.10 1.000 G/G 119 (82.1%) 86 (78.9%) 1.00
T/G 25 (17.2%) 23 (21.1%) 1.35 (0.71-2.57)
T/T 1 (0.7%) 0 (0%) NA
additive 1.19 (0.64- 2.21) 0.580 1.30 (0.67- 2.52) 0.431
3 rs11168287 48285414 G/A 0.44 0.869 G/G 43 (29.3) 36 (33.0) 1.00
A/G 72 (49.0) 57 (52.3) 0.99 (0.55- 1.76)
A/A 32 (21.8) 16 (14.7) 0.58 (0.27- 1.24)
additive 0.79 (0.55- 1.14) 0.212 0.83 (0.56- 1.23) 0.352
4 rs2238136 48277713 G/A 0.24 0.349 G/G 86 (60.1) 52 (52.5) 1.00
A/G 47 (32.9) 44 (44.4) 1.61 (0.93- 2.79)
A/A 10 (7.0) 3 (3.0) 0.47 (0.12- 1.82)
additive 1.11 (0.72- 1.72) 0.636 1.05 (0.66- 1.67) 0.845
5 rs3782905 48266167 C/G 0.36 0.483 C/C 52 (35.9) 42 (38.5) 1.00
C/G 74 (51.0) 63 (57.8) 1.07 (0.62- 1.83)
G/G 19 (13.1) 4 (3.7) 0.22 (0.07- 0.71)
additive 0.70 (0.46- 1.06) 0.134 0.69 (0.44- 1.08) 0.099
6 rs2189480 48263828 G/T 0.35 0.238 G/G ** 0.21 (0.07- 0.66)
G/G 65 (45.5) 30 (28.6) 1.00
T/G 68 (47.6) 63 (60.0) 1.92 (1.09- 3.39)
T/T 10 (7.0) 12 (11.4) 2.97 (1.12- 7.87)
additive 1.80 (1.17- 2.76) 0.006 1.66 (1.05- 2.60) 0.027
7 rs2239179 48257766 A/G 0.44 0.192 A/A 35 (23.5) 36 (33.3) 1.00
A/G 83 (55.7) 58 (53.7) 0.70 (0.39- 1.26)
G/G 31 (20.8) 14 (13.0) 0.44 (0.20- 0.99)
additive 0.67 (0.46- 0.99) 0.044 0.67 (0.44- 1.02) 0.060
8 rs11574077 48252927 T/C 0.05 0.463 T/T 129(87.8) 104 (93.7) 1.00
T/C 17 (11.6) 7 (6.3) 0.54 (0.21- 1.38)
C/C 1 (0.7) 0 (0.0) NA
additive 0.52 (0.21- 1.27) 0.135 0.45 (0.17- 1.18) 0.088
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Table 5 Association between VDR polymorphisms and nevus number (Continued)
9 rs11168267 48251542 C/T 0.07 1.000 C/C 128(85.9) 98 (88.3) 1.00
T/C 21 (14.1) 12 (10.8) 0.68 (0.32- 1.48)
T/T 0 (0.0) 1 (0.9) NA
additive 0.84 (0.41- 1.72) 0.626 0.84 (0.38- 1.84) 0.656
10 rs7975128 48245828 G/A 0.33 0.385 G/G 56 (38.6) 63 (58.9) 1.00
A/G 64 (44.1) 35 (32.7) 0.47 (0.27- 0.82)
A/A 25 (17.2) 9 (8.4) 0.29 (0.12- 0.69)
additive 0.51 (0.35- 0.76) 0.0005 0.58 (0.38- 0.87) 0.007
MAF minor allele frequency.
*SNP position from NCBI; ^ HWE Hardy –Weinberg Equilibrium for cases with low number of nevi (cases <50) as reference group; a = adjusted for age and gender; b = adjusted for age. gender and number
of melanoma.
** recessive model for SNP rs3782905.
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and in different sub-groups of the population [40-42]. The
largest study analyzed 25-hydroxyvitamin D3 level in 1262
individuals from Spain and reported 25-hydroxyvitamin
D3 insufficiency in one-third (33%) of the population [43].
Consistent with previous finding [5], there was sea-
sonal variation in serum levels of 25-hydroxyvitamin D3
where 25-hydroxyvitamin D3 levels were lower in
autumn-winter months.
The role of solar exposure in melanoma is complex as,
on the one hand, it is a strong risk factor for melanoma,
and, on the other, lack of solar exposure leads to 25-
hydroxyvitamin D3 deficiency. It has been recently
reported that regular weekend solar exposure is protect-
ive against melanoma [44] and is associated with
increased 25-hydroxyvitamin D3 levels [45]. We have
observed a correlation between less solar exposure dur-
ing adolescence and insufficient 25-hydroxyvitamin D3
levels. However this result has to be interpreted with
caution as self- reported past solar exposure is subject to
recall bias.
In our study, 25-hydroxyvitamin D3 levels at the time
of diagnosis were lower in fair-skinned patients than
darker ones. Although this relationship was no longer
statistically significant when corrected for season, this
may reflect low statistical power. However, three other
studies have in fact also reported that within white-
skinned populations, fair skinned people have lower
levels of 25-hydroxyvitamin D3 [45-47].
It was postulated that lower levels of 25-
hydroxyvitamin D3 in individuals with fair skin reflect
their habits of sun protection and in fact, this group
of patients did report fewer hours of daily sun expos-
ure and greater use of sunscreen than patients with
darker skin type (data not shown). Our results sup-
port the hypothesis that increased photoprotection
practices may contribute to increase 25-
hydroxyvitamin D3 deficiency although the results are
still contradictory [48-50].
The effects of 25-hydroxyvitamin D3 are mediated by
VDR and SNPs in this gene are expected to influence
the anti-proliferative activity of 25-hydroxyvitamin D3 in
melanocytes. The potential role of functional VDR
variants such as FokI and BsmI in melanoma risk has
been assessed by meta-analysis studies [22,23]. In our
study, significant associations have been detected be-
tween nevus number, the most potent phenotypic risk
factor of melanoma and 3 out of 11 VDR SNPs. The
SNP rs2189480 was associated with risk of having a high
number of nevi whereas SNPs rs7975128 and rs2239179
with decreased risk of having a high number of nevi. All
3 SNPs are localized in the VDR coding region between
SNPs FokI and BsmI and have been previously described
in other pathologies [50-52]. After Bonferroni correc-
tion, only SNP rs7975128 remained significant.
When we analyzed the effect of VDR variant and mel-
anoma susceptibility, we found that SNP rs7975218 was
also associated with decreased risk of multiple primary
melanomas. Recently, in a large case-only study, 8 VDR
SNPs, 6 not previously studied, were associated with
melanoma susceptibility [24]. As Orlow et al. [24] re-
port, the present work confirmed the efficiency of the
tagSNP method and showed that information about the
genetic variability of VDR is still incomplete.
According to HapMap, rs7975218 is in complete LD
(r2 = 1) with VDR functional variants BsmI and TaqI
(rs731236) which formed a block in tight LD, including
also ApaI (rs7975232), located at the 3’UTR region of
VDR. Consistent with previous findings in melanoma
where, both TaqI and BsmI have been shown to be pro-
tective against melanoma risk [21-23], SNP rs7975128
showed a protective tendency for high nevus number
and number of melanoma.
By functional study, Carling et al. [53] have demonstrated
that baT (haplotype of BsmI/ApaI/TaqI) is associated with
low VDR mRNA expression. The 3’UTR variants are
thought to affect VDR mRNA stability [18] but the func-
tionality of these variants is still unclear [22].
We also reported an association between SNP
rs7975128 and light eye color, which, with pigmentary
features such as light hair and fair skin, is considered a
melanoma risk factor related to sun exposure. Although
the significance of this association is not clear, the pres-
ence of this SNP among patients with light eye color
could suggest the involvement of the VDR gene in mel-
anoma predisposition among a subgroup of patients at
risk of low 25-hydroxyvitamin D3. Relationship between
VDR genetic variants and phenotype features among
melanoma patients has been previously described [16].
The only report in a Spanish population found signifi-
cant associations between VDR SNPs and clinical
characteristics such as fair skin, absence of childhood
sunburns and tumor in head-neck and trunk but not
with melanoma risk, suggesting that VDR may modulate
melanoma susceptibility [29].
Studies including only melanoma patients have been
shown to be valid in identifying rare genetic variants
associated with melanoma predisposition as rare variants
have a higher prevalence among cases [24,54].
The limitations of our study should be considered.
The small sample size of the two groups of patients
may affect our results; however the proportion of
patients with insufficient 25-hydroxyvitamin D3 is
comparable to a previous study in a larger melanoma
population [5]. Information regarding dietary and 25-
hydroxyvitamin D3 supplement sources, conditions
that may affect 25-hydroxyvitamin D3 levels, were
not taken into account in the analysis as not
available.
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Conclusions
Information on both serum 25-hydroxyvitamin D3 levels
and VDR variants are required to understand the role of
25-hydroxyvitamin D3 in melanoma risk. High preva-
lence of sub-optimal levels of 25-hydroxyvitamin D3 was
found among melanoma patients at diagnosis. The
relationship between VDR SNP rs7975128 and, respect-
ively, low nevus number and less multiple primary mel-
anoma, suggests the involvement of VDR, and in turn of
25-hydroxyvitamin D3, in melanoma susceptibility.
Our results provide further evidence that 25-hydro-
xyvitamin D3 could be involved in melanoma etiology in
a population from Barcelona, a Mediterranean area
characterized by a sunny climate. However this finding
needs to be validated in a larger sample.
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